2022
DOI: 10.1055/s-0042-1748924
|View full text |Cite
|
Sign up to set email alerts
|

Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma

Abstract: Liver cancer incidence rate continues to increase and currently ranks third in the total number of annual deaths, behind only lung and colorectal cancer. Most patients with hepatocellular carcinoma (HCC) are diagnosed at advanced stages, and they live for less than 2 years after diagnosis on average. This contrasts with those diagnosed at an early stage, who can be cured with surgery. However, even after curative resection, there remains a risk of up to 70% of postoperative HCC recurrence. There have been majo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 123 publications
0
3
0
Order By: Relevance
“… 25 , 33 , 34 Alpha fetoprotein may emerge as a useful screening modality for HCC in post‐SVR patients and should be investigated for this purpose, both alone and in combination with current and novel imaging methods 35 and emerging serum biomarkers. 36 Given current technologies, patients without cirrhosis who do not meet AASLD criteria for HCC surveillance, which entails abdominal ultrasound every 6 months, might benefit from serial AFP measurement.…”
Section: Discussionmentioning
confidence: 99%
“… 25 , 33 , 34 Alpha fetoprotein may emerge as a useful screening modality for HCC in post‐SVR patients and should be investigated for this purpose, both alone and in combination with current and novel imaging methods 35 and emerging serum biomarkers. 36 Given current technologies, patients without cirrhosis who do not meet AASLD criteria for HCC surveillance, which entails abdominal ultrasound every 6 months, might benefit from serial AFP measurement.…”
Section: Discussionmentioning
confidence: 99%
“…A liquid biopsy involves capturing tumor information from the blood, reflecting the body's systemic tumor information. Compared with traditional needle biopsy, liquid biopsy has the advantages of non-invasiveness, repeated sampling, real-time "update feedback" of tumor burdens, overcoming tumor heterogeneity, and guiding personalized medicine [6]. The clinical application of liquid biopsy in the clinical diagnosis and treatment of tumors includes the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), circulating microribonucleic acid (miRNA), and exosomes [3,7,8].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, novel molecular targets for HCC early diagnosis and the development of targeted therapy are critically needed. 2 Glypican-3 (GPC3), a cell-surface glycoprotein, is overexpressed in HCC tissues but not expressed in the kidneys and other liver cell types (hepatic astrocytes, endothelial cells, and fibroblasts). The increased GPC3 expression in HCC indicates the sensitivity and specificity of HCC diagnosis.…”
Section: Introductionmentioning
confidence: 99%